Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses
Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses. Immunology 2017, 152: 462-471. PMID: 28664991, PMCID: PMC5629434, DOI: 10.1111/imm.12783.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationCancer VaccinesCell SurvivalCytotoxicity, ImmunologicDelayed-Action PreparationsDendritic CellsDrug CompoundingDrug LiberationHumansInhibitor of Apoptosis ProteinsKineticsLactic AcidLipopolysaccharidesMART-1 AntigenMCF-7 CellsNanoparticlesNeoplasmsPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSolubilitySurvivinT-Lymphocytes, CytotoxicConceptsArtificial antigen-presenting cellsCytotoxic T lymphocytesT cell responsesDendritic cellsAntigen-presenting cellsTumor antigenic peptidesCTL responsesMature DCsT cellsAntigen-specific cytotoxic T lymphocytesAntigen-specific CTL responsesHuman antigen-presenting cellsCytotoxic T cell responsesHuman immature dendritic cellsEffective T cell responsesAntigenic peptidesEffective CTL responsesTumor antigen presentationCancer cellsImmature dendritic cellsMature dendritic cellsT-cell immunotherapyMHC class IMHC class I-peptide complexesWarrants further assessmentIFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells
Shao S, Risch E, Burner D, Lu L, Minev B, Ma W. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. International Immunopharmacology 2017, 47: 159-165. PMID: 28410529, DOI: 10.1016/j.intimp.2017.04.003.Peer-Reviewed Original ResearchConceptsCytotoxic T lymphocytesPositive glioma cellsT cell activation scoreMHC class IGlioma cellsClass IT lymphocytesTumor antigen-specific cytotoxic T lymphocytesAntigen-specific cytotoxic T lymphocytesIFNγ treatmentActivity of CTLHuman dendritic cellsRisk of deathHuman leukocyte antigenActivation scoresLow-grade gliomasMHC class I moleculesClass I moleculesHuman glioma cellsCytotoxic efficiencyDendritic cellsTumor immunityLeukocyte antigenCancer immunotherapyGlioma patients